Hydromorphone Quintian 10 Mg/Ml (Hydromorphone Hydrochloride)

Hydromorphone acts as an agonist at μ‑opioid receptors in the brain and spinal cord. By activating these receptors, it reduces the release of pain‑transmitting neurotransmitters, dampening the perception of pain and producing a potent analgesic effect.

The dose of Hydromorphone Quintian is individualized and must be determined by a qualified prescriber based on the patient’s pain severity, prior opioid exposure, renal and hepatic function, and other clinical factors.

Safety data for hydromorphone in pregnancy and lactation are limited. Because opioids can cause neonatal respiratory depression and may be excreted in breast milk, it is generally avoided unless the benefit outweighs the potential risk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Hydromorphone is approximately five to seven times more potent than morphine on a milligram‑per‑milligram basis, offering stronger analgesia with a smaller volume of injection. Both act on μ‑opioid receptors, but hydromorphone has a slightly shorter onset and duration, which can be advantageous in certain acute‑pain settings.

Store the product at controlled room temperature, below 25 °C, in its original packaging. Protect it from light, moisture and physical damage. Do not freeze or shake the vial before use.

Hydromorphone Quintian is supplied as a sterile solution for intravenous injection. It is administered by a qualified healthcare professional, typically as a slow push or infusion, according to the prescriber’s instructions and institutional protocols.

The most serious risks include respiratory depression, severe hypotension, anaphylactic reactions, and the potential for dependence, tolerance, or addiction. Prompt monitoring of respiratory status and vital signs is essential, especially after dose initiation or escalation.

Hydromorphone is contraindicated in patients with known hypersensitivity to hydromorphone or any component of the formulation, in those who have taken monoamine oxidase inhibitors within the past 14 days, and in individuals with significant respiratory compromise where opioid use is unsafe.